DK3804716T3 - Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf - Google Patents
Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf Download PDFInfo
- Publication number
- DK3804716T3 DK3804716T3 DK19811691.5T DK19811691T DK3804716T3 DK 3804716 T3 DK3804716 T3 DK 3804716T3 DK 19811691 T DK19811691 T DK 19811691T DK 3804716 T3 DK3804716 T3 DK 3804716T3
- Authority
- DK
- Denmark
- Prior art keywords
- combination
- sglt
- inhibitor
- composition
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810556685 | 2018-05-31 | ||
| PCT/CN2019/088863 WO2019228364A1 (zh) | 2018-05-31 | 2019-05-28 | 含有葡萄糖激酶激活剂和sglt-2抑制剂的药物组合、组合物和复方制剂及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3804716T3 true DK3804716T3 (da) | 2025-03-03 |
Family
ID=68697184
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19811377.1T DK3804715T3 (da) | 2018-05-31 | 2019-05-28 | Farmaceutisk kombination, sammensætning og forbindelsespræparat omfattende glucokinase-aktivator og dpp-iv-inhibitor, og fremgangsmåde til fremstilling og anvendelser deraf |
| DK19810783.1T DK3804714T3 (da) | 2018-05-31 | 2019-05-28 | Farmaceutisk kombination og sammensætning, og kombinationspræparat indeholdende glucokinase-aktivator og hypoglykæmisk biguanid-lægemiddel samt fremgangsmåde til fremstilling og anvendelse deraf |
| DK19811691.5T DK3804716T3 (da) | 2018-05-31 | 2019-05-28 | Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19811377.1T DK3804715T3 (da) | 2018-05-31 | 2019-05-28 | Farmaceutisk kombination, sammensætning og forbindelsespræparat omfattende glucokinase-aktivator og dpp-iv-inhibitor, og fremgangsmåde til fremstilling og anvendelser deraf |
| DK19810783.1T DK3804714T3 (da) | 2018-05-31 | 2019-05-28 | Farmaceutisk kombination og sammensætning, og kombinationspræparat indeholdende glucokinase-aktivator og hypoglykæmisk biguanid-lægemiddel samt fremgangsmåde til fremstilling og anvendelse deraf |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US20210214312A1 (da) |
| EP (6) | EP3811939A4 (da) |
| JP (12) | JP7265276B2 (da) |
| KR (7) | KR102703153B1 (da) |
| CN (12) | CN110548027B (da) |
| AU (6) | AU2019278014B2 (da) |
| BR (6) | BR112020024107A2 (da) |
| CA (4) | CA3101826A1 (da) |
| DK (3) | DK3804715T3 (da) |
| ES (3) | ES3016532T3 (da) |
| FI (3) | FI3804714T3 (da) |
| HR (3) | HRP20250257T1 (da) |
| HU (3) | HUE070297T2 (da) |
| IL (6) | IL279035B2 (da) |
| LT (3) | LT3804716T (da) |
| MX (6) | MX2020012967A (da) |
| PL (3) | PL3804716T3 (da) |
| PT (3) | PT3804716T (da) |
| RS (3) | RS66564B1 (da) |
| RU (1) | RU2770775C1 (da) |
| SG (6) | SG11202011883RA (da) |
| SI (3) | SI3804716T1 (da) |
| SM (3) | SMT202500112T1 (da) |
| TW (6) | TWI765157B (da) |
| WO (6) | WO2019228367A1 (da) |
| ZA (6) | ZA202007679B (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202011883RA (en) * | 2018-05-31 | 2020-12-30 | Hua Medicine Shanghai Ltd | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| CA3169432A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| US11813274B2 (en) | 2020-04-22 | 2023-11-14 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
| WO2021212360A1 (en) * | 2020-04-22 | 2021-10-28 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor |
| CA3185834A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| CA3185831A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CN111759838B (zh) * | 2020-07-02 | 2022-01-25 | 深圳微芯生物科技股份有限公司 | 西格列他的可药用盐药物组合物及其应用 |
| CN112206216B (zh) * | 2020-10-15 | 2023-03-17 | 江西华士药业有限公司 | 一种缓释达格列净的制备方法 |
| WO2022104621A1 (zh) * | 2020-11-19 | 2022-05-27 | 北京睿创康泰医药研究院有限公司 | 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途 |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| CN113527265B9 (zh) * | 2021-02-02 | 2022-07-19 | 湖南南新制药股份有限公司 | 一种氘代吡咯烷酮衍生物、药物组合物及其用途 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| CN113750100B (zh) * | 2021-08-31 | 2022-12-30 | 海南中济医药科技有限公司 | 一种含有多扎格列艾汀与西格列汀的药物组合物及其制备方法 |
| AR127064A1 (es) | 2021-09-15 | 2023-12-13 | Hua Medicine Shanghai Ltd | Prodroga de derivados de pirrolidona como activador de glucoquinasa |
| TR2022010735A1 (tr) * | 2022-06-29 | 2024-01-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Empagli̇flozi̇n i̇çeren bi̇r tablet |
| CN115598234B (zh) * | 2022-09-06 | 2025-05-30 | 株洲千金药业股份有限公司 | 一种检测利格列汀对映异构体的方法及应用 |
| AR132113A1 (es) * | 2023-03-13 | 2025-05-28 | Hua Medicine Shanghai Ltd | Forma sólida de derivados de pirrolidona como activador de glucoquinasa |
| CN121586585A (zh) * | 2023-04-11 | 2026-02-27 | 肽智科技私人有限公司 | 用于上调肌细胞中肌营养相关蛋白水平的化合物及其应用方法 |
| IL325046A (en) * | 2023-06-06 | 2026-02-01 | Hua Medicine Shanghai Ltd | Activates glucokinase for cognitive disorders and neurodegenerative diseases |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| CN117815193A (zh) * | 2023-11-30 | 2024-04-05 | 重庆康刻尔制药股份有限公司 | 一种盐酸二甲双胍恩格列净控释片及其制备方法 |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| US20250195440A1 (en) * | 2023-12-14 | 2025-06-19 | Hua Medicine USA Inc. | Pharmaceutical formulation comprising glucokinase activator and use thereof |
| CN120361228B (zh) * | 2025-04-08 | 2025-11-21 | 复旦大学附属妇产科医院 | 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| ITFI20010230A1 (it) | 2001-11-29 | 2003-05-29 | Menarini Int Operations Lu Sa | Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii |
| MXPA06004698A (es) | 2003-10-27 | 2006-07-05 | Innodia Inc | Metodos y composiciones para utilizarse en el tratamiento de la diabetes. |
| MXPA06004639A (es) | 2003-10-31 | 2006-06-27 | Takeda Pharmaceutical | Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano. |
| EP1734040A4 (en) * | 2004-03-23 | 2007-11-28 | Banyu Pharma Co Ltd | SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE |
| EP1884513A4 (en) | 2005-05-23 | 2010-04-28 | Japan Tobacco Inc | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7910747B2 (en) * | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US20080107725A1 (en) | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| AU2007316613B2 (en) | 2006-11-09 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions |
| AU2008305294B2 (en) * | 2007-09-21 | 2012-11-29 | Array Biopharma Inc. | Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| TWI492943B (zh) | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物(二) |
| UY32409A (es) | 2009-01-30 | 2010-08-31 | Takeda Pharmaceutical | Compuesto de anillo fusionado y su uso |
| EP2395988A2 (en) | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| MY151246A (en) * | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法 |
| CN102711738A (zh) * | 2009-11-13 | 2012-10-03 | 百时美施贵宝公司 | 质量得以减小的二甲双胍制剂 |
| JP5784623B2 (ja) * | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | 速放性錠剤製剤 |
| PT2576524T (pt) * | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| CN102558167A (zh) | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| EP2529742B1 (en) | 2011-06-03 | 2013-11-20 | ratiopharm GmbH | Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
| HK1202458A1 (en) | 2012-05-17 | 2015-10-02 | Vtv治疗有限责任公司 | Glucokinase activator compositions for the treatment of diabetes |
| ES2641469T3 (es) * | 2012-11-13 | 2017-11-10 | Nissan Chemical Industries, Ltd. | Compuesto de 2-piridona |
| TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN104208034B (zh) * | 2013-12-11 | 2017-11-07 | 重庆康刻尔制药有限公司 | 一种格列美脲药物组合物片剂、制备方法及其应用 |
| CN103655539B (zh) | 2013-12-13 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | 一种卡格列净的口服固体制剂及其制备方法 |
| CN104840960A (zh) * | 2014-02-14 | 2015-08-19 | 广东东阳光药业有限公司 | 抗糖尿病的药物组合物及其制备方法 |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US20180369325A1 (en) | 2015-11-19 | 2018-12-27 | Garvan Institute Of Medical Research | Compounds and methods for treating metabolic disorders |
| WO2017153939A1 (en) | 2016-03-10 | 2017-09-14 | Aurobindo Pharma Limited | Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof |
| CN106474480A (zh) * | 2016-11-15 | 2017-03-08 | 深圳奥萨医疗有限公司 | 含有葡萄糖激酶激动剂和b族维生素的药物组合物及其用途 |
| RU2728824C1 (ru) * | 2016-12-15 | 2020-07-31 | Хуа Медсин (Шанхай) Лтд. | Препарат активатора глюкокиназы для перорального введения и способ его получения |
| SG11202011883RA (en) * | 2018-05-31 | 2020-12-30 | Hua Medicine Shanghai Ltd | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof |
-
2019
- 2019-05-28 SG SG11202011883RA patent/SG11202011883RA/en unknown
- 2019-05-28 PT PT198116915T patent/PT3804716T/pt unknown
- 2019-05-28 BR BR112020024107-5A patent/BR112020024107A2/pt unknown
- 2019-05-28 AU AU2019278014A patent/AU2019278014B2/en not_active Ceased
- 2019-05-28 PL PL19811691.5T patent/PL3804716T3/pl unknown
- 2019-05-28 IL IL279035A patent/IL279035B2/en unknown
- 2019-05-28 CN CN201910453724.4A patent/CN110548027B/zh active Active
- 2019-05-28 SG SG11202011888VA patent/SG11202011888VA/en unknown
- 2019-05-28 SI SI201930907T patent/SI3804716T1/sl unknown
- 2019-05-28 CN CN202111601610.3A patent/CN114246950A/zh active Pending
- 2019-05-28 WO PCT/CN2019/088866 patent/WO2019228367A1/zh not_active Ceased
- 2019-05-28 RU RU2020143045A patent/RU2770775C1/ru active
- 2019-05-28 DK DK19811377.1T patent/DK3804715T3/da active
- 2019-05-28 MX MX2020012967A patent/MX2020012967A/es unknown
- 2019-05-28 LT LTEPPCT/CN2019/088863T patent/LT3804716T/lt unknown
- 2019-05-28 RS RS20250230A patent/RS66564B1/sr unknown
- 2019-05-28 LT LTEPPCT/CN2019/088864T patent/LT3804715T/lt unknown
- 2019-05-28 DK DK19810783.1T patent/DK3804714T3/da active
- 2019-05-28 KR KR1020207037642A patent/KR102703153B1/ko active Active
- 2019-05-28 CA CA3101826A patent/CA3101826A1/en active Pending
- 2019-05-28 SG SG11202011881PA patent/SG11202011881PA/en unknown
- 2019-05-28 MX MX2020012970A patent/MX2020012970A/es unknown
- 2019-05-28 RS RS20250231A patent/RS66565B1/sr unknown
- 2019-05-28 FI FIEP19810783.1T patent/FI3804714T3/fi active
- 2019-05-28 HR HRP20250257TT patent/HRP20250257T1/hr unknown
- 2019-05-28 CN CN201910453726.3A patent/CN110548149B/zh active Active
- 2019-05-28 CA CA3101825A patent/CA3101825A1/en active Pending
- 2019-05-28 CN CN202111599339.4A patent/CN114209694A/zh active Pending
- 2019-05-28 DK DK19811691.5T patent/DK3804716T3/da active
- 2019-05-28 PT PT198113771T patent/PT3804715T/pt unknown
- 2019-05-28 EP EP19812252.5A patent/EP3811939A4/en not_active Withdrawn
- 2019-05-28 JP JP2020566675A patent/JP7265276B2/ja active Active
- 2019-05-28 ES ES19810783T patent/ES3016532T3/es active Active
- 2019-05-28 BR BR112020024125-3A patent/BR112020024125A2/pt unknown
- 2019-05-28 CN CN202111599185.9A patent/CN114028574A/zh active Pending
- 2019-05-28 AU AU2019278013A patent/AU2019278013B2/en active Active
- 2019-05-28 SM SM20250112T patent/SMT202500112T1/it unknown
- 2019-05-28 CN CN202111599191.4A patent/CN114159570B/zh active Active
- 2019-05-28 WO PCT/CN2019/088861 patent/WO2019228362A1/zh not_active Ceased
- 2019-05-28 SG SG11202011886TA patent/SG11202011886TA/en unknown
- 2019-05-28 PL PL19811377.1T patent/PL3804715T3/pl unknown
- 2019-05-28 KR KR1020207037957A patent/KR20210016437A/ko not_active Ceased
- 2019-05-28 HU HUE19811377A patent/HUE070297T2/hu unknown
- 2019-05-28 FI FIEP19811691.5T patent/FI3804716T3/fi active
- 2019-05-28 PT PT198107831T patent/PT3804714T/pt unknown
- 2019-05-28 CN CN201910453723.XA patent/CN110548026B/zh active Active
- 2019-05-28 CN CN201910453079.6A patent/CN110548147B/zh active Active
- 2019-05-28 JP JP2020566720A patent/JP2021525741A/ja active Pending
- 2019-05-28 CN CN202111601620.7A patent/CN114259491A/zh active Pending
- 2019-05-28 LT LTEPPCT/CN2019/088861T patent/LT3804714T/lt unknown
- 2019-05-28 BR BR112020024271-3A patent/BR112020024271A2/pt not_active Application Discontinuation
- 2019-05-28 SI SI201930906T patent/SI3804715T1/sl unknown
- 2019-05-28 CA CA3101832A patent/CA3101832A1/en active Pending
- 2019-05-28 KR KR1020207037950A patent/KR102695130B1/ko active Active
- 2019-05-28 KR KR1020207037560A patent/KR102695135B1/ko active Active
- 2019-05-28 HR HRP20250268TT patent/HRP20250268T1/hr unknown
- 2019-05-28 AU AU2019278015A patent/AU2019278015B2/en active Active
- 2019-05-28 WO PCT/CN2019/088862 patent/WO2019228363A1/zh not_active Ceased
- 2019-05-28 AU AU2019278016A patent/AU2019278016B2/en active Active
- 2019-05-28 EP EP19811377.1A patent/EP3804715B1/en active Active
- 2019-05-28 WO PCT/CN2019/088864 patent/WO2019228365A1/zh not_active Ceased
- 2019-05-28 US US17/058,929 patent/US20210214312A1/en not_active Abandoned
- 2019-05-28 CA CA3101822A patent/CA3101822C/en active Active
- 2019-05-28 BR BR112020024348-5A patent/BR112020024348A2/pt unknown
- 2019-05-28 SG SG11202011884QA patent/SG11202011884QA/en unknown
- 2019-05-28 AU AU2019278017A patent/AU2019278017A1/en not_active Abandoned
- 2019-05-28 US US17/058,863 patent/US11666556B2/en active Active
- 2019-05-28 EP EP19810783.1A patent/EP3804714B1/en active Active
- 2019-05-28 KR KR1020207038034A patent/KR102695132B1/ko active Active
- 2019-05-28 RS RS20250232A patent/RS66566B1/sr unknown
- 2019-05-28 CN CN201910453076.2A patent/CN110548146B/zh active Active
- 2019-05-28 SI SI201930909T patent/SI3804714T1/sl unknown
- 2019-05-28 ES ES19811377T patent/ES3015131T3/es active Active
- 2019-05-28 IL IL279039A patent/IL279039B2/en unknown
- 2019-05-28 HU HUE19810783A patent/HUE070296T2/hu unknown
- 2019-05-28 JP JP2020566718A patent/JP7565589B2/ja active Active
- 2019-05-28 WO PCT/CN2019/088863 patent/WO2019228364A1/zh not_active Ceased
- 2019-05-28 BR BR112020024203-9A patent/BR112020024203A2/pt not_active Application Discontinuation
- 2019-05-28 SG SG11202011893UA patent/SG11202011893UA/en unknown
- 2019-05-28 MX MX2020012966A patent/MX2020012966A/es unknown
- 2019-05-28 IL IL279037A patent/IL279037B2/en unknown
- 2019-05-28 SM SM20250104T patent/SMT202500104T1/it unknown
- 2019-05-28 CN CN202111601625.XA patent/CN114010793B/zh active Active
- 2019-05-28 CN CN201910453725.9A patent/CN110548148B/zh active Active
- 2019-05-28 KR KR1020247017725A patent/KR20240091095A/ko not_active Abandoned
- 2019-05-28 MX MX2020012965A patent/MX2020012965A/es unknown
- 2019-05-28 HU HUE19811691A patent/HUE070298T2/hu unknown
- 2019-05-28 BR BR112020024269-1A patent/BR112020024269A2/pt not_active Application Discontinuation
- 2019-05-28 MX MX2020012969A patent/MX2020012969A/es unknown
- 2019-05-28 EP EP19810441.6A patent/EP3804713A4/en not_active Withdrawn
- 2019-05-28 EP EP19811691.5A patent/EP3804716B1/en active Active
- 2019-05-28 US US17/058,883 patent/US11992477B2/en active Active
- 2019-05-28 IL IL279036A patent/IL279036B2/en unknown
- 2019-05-28 US US17/058,936 patent/US12064416B2/en active Active
- 2019-05-28 SM SM20250107T patent/SMT202500107T1/it unknown
- 2019-05-28 WO PCT/CN2019/088865 patent/WO2019228366A1/zh not_active Ceased
- 2019-05-28 PL PL19810783.1T patent/PL3804714T3/pl unknown
- 2019-05-28 US US17/059,148 patent/US12318366B2/en active Active
- 2019-05-28 ES ES19811691T patent/ES3017250T3/es active Active
- 2019-05-28 FI FIEP19811377.1T patent/FI3804715T3/fi active
- 2019-05-28 AU AU2019278018A patent/AU2019278018B2/en not_active Ceased
- 2019-05-28 US US17/058,903 patent/US11963947B2/en active Active
- 2019-05-28 JP JP2020566710A patent/JP2021525739A/ja active Pending
- 2019-05-28 EP EP19810210.5A patent/EP3804712A4/en not_active Withdrawn
- 2019-05-28 HR HRP20250258TT patent/HRP20250258T1/hr unknown
- 2019-05-28 MX MX2020012972A patent/MX2020012972A/es unknown
- 2019-05-28 JP JP2020566564A patent/JP7479696B2/ja active Active
- 2019-05-28 KR KR1020207037631A patent/KR102695126B1/ko active Active
- 2019-05-28 JP JP2020566565A patent/JP2021525722A/ja active Pending
- 2019-05-31 TW TW108118937A patent/TWI765157B/zh not_active IP Right Cessation
- 2019-05-31 TW TW108118936A patent/TWI764000B/zh active
- 2019-05-31 TW TW108118940A patent/TWI778268B/zh active
- 2019-05-31 TW TW108118901A patent/TWI794503B/zh active
- 2019-05-31 TW TW108118896A patent/TWI761681B/zh active
- 2019-05-31 TW TW108118939A patent/TWI706947B/zh active
-
2020
- 2020-11-27 IL IL279040A patent/IL279040A/en unknown
- 2020-11-27 IL IL279034A patent/IL279034A/en unknown
- 2020-12-09 ZA ZA2020/07679A patent/ZA202007679B/en unknown
- 2020-12-09 ZA ZA2020/07687A patent/ZA202007687B/en unknown
- 2020-12-09 ZA ZA2020/07671A patent/ZA202007671B/en unknown
- 2020-12-09 ZA ZA2020/07678A patent/ZA202007678B/en unknown
- 2020-12-09 ZA ZA2020/07688A patent/ZA202007688B/en unknown
- 2020-12-09 ZA ZA2020/07681A patent/ZA202007681B/en unknown
-
2022
- 2022-11-07 JP JP2022178296A patent/JP2022190165A/ja active Pending
- 2022-11-07 JP JP2022178269A patent/JP2022190162A/ja active Pending
- 2022-11-07 JP JP2022178385A patent/JP2022190170A/ja active Pending
- 2022-11-07 JP JP2022178345A patent/JP2022190168A/ja active Pending
- 2022-11-07 JP JP2022178239A patent/JP2022190161A/ja active Pending
- 2022-11-07 JP JP2022178201A patent/JP2022190159A/ja active Pending
-
2023
- 2023-05-03 US US18/311,846 patent/US20230346748A1/en not_active Abandoned
-
2024
- 2024-03-19 US US18/610,100 patent/US20240299357A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3804716T3 (da) | Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf | |
| DK4053241T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, lagring og anvendelse deraf | |
| EP3835296A4 (en) | KETOAMIDE COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| DK3312177T3 (da) | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme | |
| DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| DK3408326T3 (da) | Elastomerartikler, sammensætninger og fremgangsmåder til fremstilling deraf | |
| DK3328844T3 (da) | 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme | |
| EP3197867A4 (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| DK3576788T3 (da) | Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner | |
| DK2986304T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf. | |
| DK3380529T3 (da) | Aktiverede pektinholdige biomassesammensætninger, produkter og fremgangsmåder til fremstilling heraf | |
| PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
| DK4428234T3 (da) | Direkte-til-bibliotek-fremgangsmåder, systemer og sammensætninger | |
| DK3573472T3 (da) | Granuleret kosttilskud og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3750893T3 (da) | Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf | |
| DK3858833T3 (da) | Aminonorbornanderivat, fremgangsmåde til fremstilling heraf og anvendelse heraf | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR | |
| DK3604303T3 (da) | Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf | |
| DK4023651T3 (da) | Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
| DK3712162T3 (da) | Smac-mimetica anvendt som iap-inhibitorer og anvendelse deraf | |
| WO2016109361A3 (en) | 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase | |
| DK3534981T3 (da) | Amnionvævstransplantater og fremgangsmåder til fremstilling og anvendelse deraf | |
| IL266659B (en) | fgfr4 inhibitor, a pharmaceutical preparation containing it and its use |